Signaling interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells

Frontiers in Endocrinology

Volumn 7, Issue , 2016, Pages

  Falank, Carolyne ^a   Fairfield, H Heather ^a   Reagan, Michaela R ^a,b,c  

^a Maine Medical Center Research Institute   (United States)

^b UNIVERSITY OF MAINE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipocyte; BMAT; Bone marrow adipose; Bone metastasis; Fatty acids; MAT; Microenvironment; Multiple myeloma

Indexed keywords

ADIPONECTIN; ANDROGEN; COLLAGENASE 3; DICKKOPF 1 PROTEIN; DOCOSAHEXAENOIC ACID; GLUCOSE TRANSPORTER 3; ICOSAPENTAENOIC ACID; INSULIN; LACTATE DEHYDROGENASE; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR FOXC2; TUMOR NECROSIS FACTOR RECEPTOR; UNCOUPLING PROTEIN 1; VASCULOTROPIN; ZINC FINGER PROTEIN;

ADIPOCYTE; ADIPOSE DERIVED STEM CELL; ADIPOSE TISSUE; ARTICLE; BONE DISEASE; BONE MARROW; BONE MARROW ADIPOSE TISSUE; BONE REMODELING; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; HEMATOPOIESIS; LIPID METABOLISM; MESENCHYMAL STROMA CELL; MULTIPLE MYELOMA; TRANSCRIPTION REGULATION; TUMOR GROWTH; WHITE ADIPOSE TISSUE;

EID: 84978880231     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2016.00067     Document Type: Article

References (183)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57-70. doi:10.1016/S0092-8674(00)81683-9
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med (2011) 364: 1046-60. doi:10.1056/NEJMra1011442
4. Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 1364:32-51. doi:10.1111/nyas.13038
5. Reagan MR, Ghobrial IM. Multiple myeloma-mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res (2012) 18:342-9. doi:10.1158/1078-0432.CCR-11-2212
6. Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev (2015) 263:160-72. doi:10.1111/imr.12233
7. Alexander DD, Mink PJ, Adami H-O, Cole P, Mandel JS, Oken MM, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer (2007) 120(Suppl):40-61. doi:10.1002/ijc.22718
8. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol (2015) 33:2863-9. doi:10.1200/JCO.2015.61.2267
9. Wright JH. A case of multiple myeloma. J Boston Soc Med Sci (1900) 4:195-204.5.
10. Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K, et al. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol (2014) 166:667-76. doi:10.1111/bjh.12935
11. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Månsson R, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell (2007) 1:671-84. doi:10.1016/j.stem.2007.10.008
12. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 25:91-101. doi:10.1016/j.ccr.2013.12.015
13. Sahin I, Azab F, Mishima Y, Moschetta M, Tsang B, Glavey SV, et al. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. Am J Hematol (2014) 89:1030-6. doi:10.1002/ajh.23814
14. Brunetti G, Rizzi R, Oranger A, Gigante I, Mori G, Taurino G, et al. LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. Oncotarget (2014) 5:12950-67. doi:10.18632/oncotarget.2633
15. Suen H, Brown R, Yang S, Weatherburn C, Ho PJ, Woodland N, et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia (2016). doi:10.1038/leu.2016.84
16. Fu J, Li S, Feng R, Ma H, Sabeh F, Roodman GD, et al. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J Clin Invest (2016) 126:1759-72. doi:10.1172/JCI80276
17. Colucci S, Brunetti G, Mori G, Oranger A, Centonze M, Mori C, et al. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia (2009) 23:2139-46. doi:10.1038/leu.2009.136
18. Reagan MR, Liaw L, Rosen CJ, Ghobrial IM. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone (2015) 75:161-9. doi:10.1016/j.bone.2015.02.021
19. Palma BD, Guasco D, Pedrazzoni M, Bolzoni M, Accardi F, Costa F, et al. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20. Leukemia (2016) 30:409-16. doi:10.1038/leu.2015.259
20. Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, et al. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer J (2016) 6:e378. doi:10.1038/bcj.2015.96
21. Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 16:373-86. doi:10.1038/nrc. 2016.44
22. Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res (2003) 63:287-9.
23. Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A (2014) 111:10287-92. doi:10.1073/ pnas.1401337111
24. Lawson MA, McDonald MM, Kovacic NN, Hua Khoo W, Terry RTL, Down J, et al. Osteoclasts control re-activation of dormant myeloma cells by remodeling the endosteal niche. Nat Commun (2015) 6:8983. doi:10.1038/ ncomms9983
25. Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, et al. Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia (2016) 30:1103-15. doi:10.1038/leu.2016.3
26. Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A, et al. Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta (2014) 1846:26-39. doi:10.1016/j.bbcan.2014.03.005
27. Glavey SV, Huynh D, Reagan MR, Manier S, Moschetta M, Kawano Y, et al. The cancer glycome: carbohydrates as mediators of metastasis. Blood Rev (2015) 29:269-79. doi:10.1016/j.blre.2015.01.003
28. Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, et al. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood (2014) 124(11):1765-76. doi:10.1182/blood-2014-03-560862
29. Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood (2011) 119:1468-78. doi:10.1182/blood-2011-07-368050
30. Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep (2014) 9:118-28. doi:10.1016/j.celrep.2014.08.042
31. Azab AK, Runnels JM, Pitsillides C, Moreau A-S, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 113:4341-51. doi:10.1182/blood-2008-10-186668
32. Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, et al. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood (2014) 124:3250-9. doi:10.1182/ blood-2014-02-558007
33. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai Y-T, Reagan M, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 123:1542-55. doi:10.1172/JCI66517
34. Manni S, Toscani D, Mandato E, Brancalion A, Quotti Tubi L, Macaccaro P, et al. Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia (2014) 28:2094-7. doi:10.1038/leu.2014.178
35. Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, et al. Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res (2016) 76:1089-100. doi:10.1158/0008-5472.CAN-15-1703
36. Colaianni G, Colucci S, Grano M. 1st ed. In: Lenzi A, Migliaccio S, Maria Donini L, editors. Multidisciplinary Approach to Obesity: From Assessment to Treatment. Switzerland: Springer International Publishing (2015). Available from: http://www.springer.com/us/book/9783319090443
37. Scheller EL, Rosen CJ. What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Ann N Y Acad Sci (2014) 1311:14-30. doi:10.1111/nyas.12327
38. Lecka-Czernik B. Marrow fat metabolism is linked to the systemic energy metabolism. Bone (2012) 50:534-9. doi:10.1016/j.bone.2011.06.032
39. Poloni A, Maurizi G, Serrani F, Mancini S, Zingaretti MC, Frontini A, et al. Molecular and functional characterization of human bone marrow adipocytes. Exp Hematol (2013) 41:558-566.e2. doi:10.1016/j.exphem.2013.02.005
40. Lecka-Czernik B, Stechschulte LA. Bone and fat: a relationship of different shades. Arch Biochem Biophys (2014) 561:124-9. doi:10.1016/j. abb.2014.06.010
41. Devlin MJ, Cloutier AM, Thomas NA, Panus DA, Lotinun S, Pinz I, et al. Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res (2010) 25:2078-88. doi:10.1002/jbmr.82
42. Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab (2014) 20:368-75. doi:10.1016/j.cmet.2014.06.003
43. Xuan D, Han Q, Tu Q, Zhang L, Yu L, Murry D, et al. Epigenetic modulation in periodontitis: interaction of adiponectin and JMJD3-IRF4 axis in macrophages. J Cell Physiol (2016) 231:1090-6. doi:10.1002/jcp.25201
44. Adler BJ, Kaushansky K, Rubin CT. Obesity-driven disruption of haematopoiesis and the bone marrow niche. Nat Rev Endocrinol (2014) 10:737-48. doi:10.1038/nrendo.2014.169
45. Doucette CR, Horowitz MC, Berry R, MacDougald OA, Anunciado-Koza R, Koza RA, et al. A high fat diet increases bone marrow adipose tissue (MAT) but does not alter trabecular or cortical bone mass in C57BL/6J mice. J Cell Physiol (2015) 230(9):2032-7. doi:10.1002/jcp.24954
46. Scheller EL, Cawthorn WP, Burr AA, Horowitz MC, MacDougald OA. Marrow adipose tissue: trimming the fat. Trends Endocrinol Metab (2016) 27:392-403. doi:10.1016/j.tem.2016.03.016
47. Scheller EL, Troiano N, Vanhoutan JN, Bouxsein MA, Fretz JA, Xi Y, et al. Use of osmium tetroxide staining with microcomputerized tomography to visualize and quantify bone marrow adipose tissue in vivo. Methods Enzymol (2014) 537:123-39. doi:10.1016/B978-0-12-411619-1.00007-0
48. Bredella MA, Lin E, Gerweck AV, Landa MG, Thomas BJ, Torriani M, et al. Determinants of bone microarchitecture and mechanical properties in obese men. J Clin Endocrinol Metab (2012) 97:4115-22. doi:10.1210/jc.2012-2246
49. Miyakoshi N, Sato K, Abe T, Tsuchida T, Tamura Y, Kudo T. Histomorphometric evaluation of the effects of ovariectomy on bone turnover in rat caudal vertebrae. Calcif Tissue Int (1999) 64:318-24. doi:10.1007/s002239900626
50. Li M, Shen Y, Qi H, Wronski TJ. Comparative study of skeletal response to estrogen depletion at red and yellow marrow sites in rats. Anat Rec (1996) 245:472-80. doi:10.1002/(SICI)1097-0185(199607)245:3472:AID-AR33.0.CO;2-U
51. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature (2009) 460:259-63. doi:10.1038/nature08099
52. Bornstein S, Brown SA, Le PT, Wang X, DeMambro V, Horowitz MC, et al. FGF-21 and skeletal remodeling during and after lactation in C57BL6 mice. Endocrinology (2014) 155:3516-26. doi:10.1210/en.2014-1083
53. Ackert-Bicknell CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA, Rosen CJ. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology (2009) 150:1330-40. doi:10.1210/en.2008-0936
54. Reagan MR, Rosen CJ. Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol (2015) 12:154-68. doi:10.1038/nrrheum.2015.160
55. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr (2009) 19:109-24. doi:10.1016/j. bbi.2008.05.010
56. Fazeli PK, Horowitz MC, MacDougald OA, Scheller EL, Rodeheffer MS, Rosen CJ, et al. Marrow fat and bone-new perspectives. J Clin Endocrinol Metab (2013) 98:935-45. doi:10.1210/jc.2012-3634
57. Roura S, Farré J, Soler-Botija C, Llach A, Hove-Madsen L, Cairó JJ, et al. Effect of aging on the pluripotential capacity of human CD105+ mesenchymal stem cells. Eur J Heart Fail (2006) 8:555-63. doi:10.1016/j.ejheart.2005.11.006
58. Kretlow JD, Jin Y-Q, Liu W, Zhang WJ, Hong T-H, Zhou G, et al. Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol (2008) 9:60. doi:10.1186/1471-2121-9-60
59. Maredziak M, Marycz K, Tomaszewski KA, Kornicka K, Henry BM. The influence of aging on the regenerative potential of human adipose derived mesenchymal stem cells. Stem Cells Int (2016) 2016:1-15. doi:10.1155/2016/2152435
60. Singh L, Brennan TA, Russell E, Kim J-H, Chen Q, Brad Johnson F, et al. Aging alters bone-fat reciprocity by shifting in vivo mesenchymal precursor cell fate towards an adipogenic lineage. Bone (2016) 85:29-36. doi:10.1016/j. bone.2016.01.014
61. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell (2014) 15:154-68. doi:10.1016/j. stem.2014.06.008
62. Liu Y, Strecker S, Wang L, Kronenberg MS, Wang W, Rowe DW, et al. Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS One (2013) 8:e71318. doi:10.1371/journal. pone.0071318
63. Pan SY, Johnson KC, Ugnat A-M, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol (2004) 159:259-68. doi:10.1093/ aje/kwh041
64. Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer (2011) 47:1606-15. doi:10.1016/j.ejca.2011.01.020
65. Islam R, Altundag K, Kurt M, Altundag O, Turen S. Association between obesity and multiple myeloma in postmenopausal women may be attributed to increased aromatization of androgen in adipose tissue. Med Hypotheses (2005) 65:1001-2. doi:10.1016/j.mehy.2005.05.014
66. Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia (2007) 21:1580-4. doi:10.1038/ sj.leu.2404658
67. Liu Z, Xu J, He J, Liu H, Lin P, Wan X, et al. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget (2015) 6:34329-41. doi:10.18632/oncotarget.6020
68. Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD, Barlogie B, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood (2009) 113:4614-26. doi:10.1182/blood-2008-07-170464
69. Clark R, Krishnan V, Schoof M, Rodriguez I, Theriault B, Chekmareva M, et al. Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am J Pathol (2013) 183:576-91. doi:10.1016/j.ajpath.2013.04.023
70. Vogl DT, Wang T, Pérez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant (2011) 17:1765-74. doi:10.1016/j.bbmt.2011.05.005
71. Zub KA, Sousa MM, Sarno A, Sharma A, Demirovic A, Rao S, et al. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells. PLoS One (2015) 10:e0119857. doi:10.1371/journal.pone.0119857
72. Nagata Y, Ishizaki I, Waki M, Ide Y, Hossen MA, Ohnishi K, et al. Palmitic acid, verified by lipid profiling using secondary ion mass spectrometry, demonstrates anti-multiple myeloma activity. Leuk Res (2015) 39:638-45. doi:10.1016/j.leukres.2015.02.011
73. Zou J, Ma X, Zhang G, Shen L, Zhou L, Yu Y, et al. Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide. J Chromatogr B Analyt Technol Biomed Life Sci (2015) 1004:98-107. doi:10.1016/j. jchromb.2015.09.015
74. Kitatani K, Taniguchi M, Okazaki T. Role of sphingolipids and metabolizing enzymes in hematological malignancies. Mol Cells (2015) 38:482-95. doi:10.14348/molcells.2015.0118
75. Jurczyszyn A, Czepiel J, Gdula-Argasinska J, Pasko P, Czapkiewicz A, Librowski T, et al. Plasma fatty acid profile in multiple myeloma patients. Leuk Res (2015) 39:400-5. doi:10.1016/j.leukres.2014.12.010
76. Hossen MA, Nagata Y, Waki M, Ide Y, Takei S, Fukano H, et al. Decreased level of phosphatidylcholine (16:0/20:4) in multiple myeloma cells compared to plasma cells: a single-cell MALDI-IMS approach. Anal Bioanal Chem (2015) 407:5273-80. doi:10.1007/s00216-015-8741-z
77. Spindler TJ, Tseng AW, Zhou X, Adams GB. Adipocytic cells augment the support of primitive hematopoietic cells in vitro but have no effect in the bone marrow niche under homeostatic conditions. Stem Cells Dev (2014) 23:434-41. doi:10.1089/scd.2013.0227
78. Sola B, Poirot M, de Medina P, Bustany S, Marsaud V, Silvente-Poirot S, et al. Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. Oncotarget (2013) 4:911-22. doi:10.18632/oncotarget.1066
79. Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med (2016) 374:555-61. doi:10.1056/NEJMoa1508808
80. Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Der Danielian M, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol (1995) 155:2487-97.
81. Klein-Wieringa IR, Andersen SN, Kwekkeboom JC, Giera M, de Lange-Brokaar BJE, van Osch GJVM, et al. Adipocytes modulate the phenotype of human macrophages through secreted lipids. J Immunol (2013) 191:1356-63. doi:10.4049/jimmunol.1203074
82. Krishnan A, Nair SA, Pillai MR. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med (2007) 7:532-40. doi:10.2174/156652407781695765
83. Aouali N, Broukou A, Bosseler M, Keunen O, Schlesser V, Janji B, et al. Epigenetic activity of peroxisome proliferator-activated receptor gamma agonists increases the anticancer effect of histone deacetylase inhibitors on multiple myeloma cells. PLoS One (2015) 10:e0130339. doi:10.1371/journal. pone.0130339
84. Rui M, Huang Z, Liu Y, Wang Z, Liu R, Fu J, et al. Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1a and insulin-like growth factor-1 mRNA expression. Mol Med Rep (2014) 10:2137-43. doi:10.3892/mmr.2014.2407
85. Cao D, Zhou H, Zhao J, Jin L, Yu W, Yan H, et al. PGC-1a integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4. Oncol Rep (2014) 31:1205-10. doi:10.3892/or.2014.2974
86. Kim SY, Min HJ, Park HK, Oh B, Kim TY, She CJ, et al. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation. Biol Blood Marrow Transplant (2011) 17:810-20. doi:10.1016/j.bbmt.2011.01.002
87. Greco EA, Lenzi A, Migliaccio S. The obesity of bone. Ther Adv Endocrinol Metab (2015) 6:273-86. doi:10.1177/2042018815611004
88. Sakurai T, Ogasawara J, Kizaki T, Sato S, Ishibashi Y, Takahashi M, et al. The effects of exercise training on obesity-induced dysregulated expression of adipokines in white adipose tissue. Int J Endocrinol (2013) 2013:801743. doi:10.1155/2013/801743
89. Galson DL, Silbermann R, Roodman GD. Mechanisms of multiple myeloma bone disease. Bonekey Rep (2012) 1:135. doi:10.1038/bonekey.2012.135
90. Lee C, Oh J-I, Park J, Choi J-H, Bae E-K, Lee HJ, et al. TNF a mediated IL-6 secretion is regulated by JAK/STAT pathway but not by MEK phosphorylation and AKT phosphorylation in U266 multiple myeloma cells. Biomed Res Int (2013) 2013:580135. doi:10.1155/2013/580135
91. Jöhrer K, Janke K, Krugmann J, Fiegl M, Greil R. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res (2004) 10:1901-10. doi:10.1158/1078-0432.CCR-1053-03
92. Yagci M, Sucak GT, Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol (2003) 74:231-7. doi:10.1002/ajh.10433
93. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature (2000) 404:661-71. doi:10.1038/ 35007534
94. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol (2011) 11:85-97. doi:10.1038/nri2921
95. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 27:412-21. doi:10.1111/j.1365-2036.2007.03586.x
96. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol (2012) 216:T17-36. doi:10.1530/JOE-12-0232
97. Sood A. Obesity, adipokines, and lung disease. J Appl Physiol (2009) 108:744-53. doi:10.1152/japplphysiol.00838.2009
98. Waluga M, Hartleb M, Boryczka G, Kukla M, Zwirska-Korczala K. Serum adipokines in inflammatory bowel disease. World J Gastroenterol (2014) 20:6912-7. doi:10.3748/wjg.v20.i22.6912
99. Hofmann JN, Liao LM, Pollak MN, Wang YY, Pfeiffer RM, Baris D, et al. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood (2012) 120:4418-20. doi:10.1182/blood-2012-06-438606
100. Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, et al. Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol (2009) 83:460-70. doi:10.1111/j.1600-0609.2009.01311.x
101. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 33:547-94. doi:10.1210/er.2011-1015
102. Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidakis E, et al. Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers (2004) 19:52-7.
103. Mouzaki A, Panagoulias I, Dervilli Z, Zolota V, Spadidea P, Rodi M, et al. Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells. Cytokine (2009) 48:203-11. doi:10.1016/j.cyto.2009.07.006
104. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone (2004) 35:842-9. doi:10.1016/j.bone.2004.06.008
105. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 257:79-83. doi:10.1006/bbrc.1999.0255
106. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 20:1595-9. doi:10.1161/01.ATV.20.6.1595
107. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-expression. Diabetes (2003) 52:1779-85. doi:10.2337/diabetes.52.7.1779
108. Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control (2009) 20:193-9. doi:10.1007/s10552-008-9233-7
109. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res (2003) 9:5699-704.
110. Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR, et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 118:5872-82. doi:10.1182/blood-2011-01-330407
111. Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GVN, Oyajobi BO. PKA/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells. Leukemia (2014) 28:2080-9. doi:10.1038/ leu.2014.112
112. Zhou Y, Rui L. Leptin signaling and leptin resistance. Front Med (2013) 7:207-22. doi:10.1007/s11684-013-0263-5
113. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature (1997) 387:903-8. doi:10.1038/43185
114. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med (1999) 341:879-84. doi:10.1056/NEJM 199909163411204
115. Kopelman PG. Obesity as a medical problem. Nature (2000) 404:635-43. doi:10.1038/35007508
116. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther (2009) 8:1974-84. doi:10.1158/1535-7163.MCT-08-1177
117. Arner P. Resistin: yet another adipokine tells us that men are not mice. Diabetologia (2005) 48:2203-5. doi:10.1007/s00125-005-1956-3
118. Ukkola O. Resistin -a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol (2002) 147:571-4. doi:10.1530/ eje.0.1470571
119. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF, et al. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia (2010) 24:1940-50. doi:10.1038/leu. 2010.192
120. Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature (2014) 508:269-73. doi:10.1038/nature13034
121. Amorin B, Alegretti AP, de Souza Valim V, da Silva AMP, da Silva MAL, Sehn F, et al. Characteristics of mesenchymal stem cells under hypoxia. CellBio (2013) 2:11-9. doi:10.4236/cellbio.2013.21002
122. Kakudo N, Morimoto N, Ogawa T, Taketani S, Kusumoto K. Hypoxia enhances proliferation of human adipose-derived stem cells via HIF-1a activation. PLoS One (2015) 10:e0139890. doi:10.1371/journal.pone. 0139890
123. Borsi E, Perrone G, Terragna C, Martello M, Dico AF, Solaini G, et al. Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget (2014) 5:1779-92. doi:10.18632/oncotarget.1736
124. Yata K, Otsuki T, Kurebayashi J, Uno M, Fujii T, Yawata Y, et al. Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells. Int J Oncol (2003) 22:165-73. doi:10.3892/ ijo.22.1.165
125. Muz B, de la Puente P, Azab F, Luderer M, Azab AK. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J (2014) 4:e262. doi:10.1038/bcj.2014.82
126. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood (2012) 119:5782-94. doi:10.1182/blood-2011-09-380410
127. Zhang Y, Marsboom G, Toth PT, Rehman J. Mitochondrial respiration regulates adipogenic differentiation of human mesenchymal stem cells. PLoS One (2013) 8:e77077. doi:10.1371/journal.pone.0077077
128. Cicione C, Muiños-López E, Hermida-Gómez T, Fuentes-Boquete I, Díaz-Prado S, Blanco FJ. Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential. Stem Cells Int (2013) 2013:232896. doi:10.1155/2013/232896
129. Pachón-Peña G, Serena C, Ejarque M, Petriz J, Duran X, Oliva-Olivera W, et al. Obesity determines the immunophenotypic profile and functional characteristics of human mesenchymal stem cells from adipose tissue. Stem Cells Transl Med (2016) 5:464-75. doi:10.5966/sctm.2015-0161
130. Wu C-L, Diekman BO, Jain D, Guilak F. Diet-induced obesity alters the differentiation potential of stem cells isolated from bone marrow, adipose tissue and infrapatellar fat pad: the effects of free fatty acids. Int J Obes (Lond) (2013) 37:1079-87. doi:10.1038/ijo.2012.171
131. Hu J, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K. Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech (2012) 5:763-71. doi:10.1242/dmm.008961
132. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 16:4604-13. doi:10.1128/MCB.16.9.4604
133. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood (2005) 105:1383-95. doi:10.1182/blood-2004-07-2909
134. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 92:2908-13.
135. Bolkun L, Lemancewicz D, Sobolewski K, Mantur M, Semeniuk J, Kulczynska A, et al. The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment. Adv Med Sci (2013) 58:118-25. doi:10.2478/ v10039-012-0048-0
136. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res (1997) 67:147-54. doi:10.1006/jsre.1996.4983
137. Soukas A, Socci ND, Saatkamp BD, Novelli S, Friedman JM. Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem (2001) 276:34167-74. doi:10.1074/jbc.M104421200
138. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, Kim KW. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene (2000) 19:4621-31. doi:10.1038/ sj.onc.1203814
139. Wang F, Zhang W, Guo L, Bao W, Jin N, Liu R, et al. Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1a/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/ mammalian target protein of rapamycin pathway in multiple myeloma cells. Cancer Sci (2014) 105:1063-70. doi:10.1111/cas.12458
140. de Waal EGM, Slart RHJA, Leene MJ, Kluin PM, Vellenga E. 18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven? Clin Nucl Med (2015) 40:291-6. doi:10.1097/ RLU.0000000000000629
141. Almendros I, Gileles-Hillel A, Khalyfa A, Wang Y, Zhang SX, Carreras A, et al. Adipose tissue macrophage polarization by intermittent hypoxia in a mouse model of OSA: effect of tumor microenvironment. Cancer Lett (2015) 361:233-9. doi:10.1016/j.canlet.2015.03.010
142. Kugel H, Jung C, Schulte O, Heindel W. Age-and sex-specific differences in the 1H-spectrum of vertebral bone marrow. J Magn Reson Imaging (2001) 13: 263-8. doi:10.1002/1522-2586(200102)13:2263::AID-JMRI10383.3.CO;2-D
143. Griffith JF, Yeung DKW, Antonio GE, Wong SYS, Kwok TCY, Woo J, et al. Vertebral marrow fat content and diffusion and perfusion indexes in women with varying bone density: MR evaluation. Radiology (2006) 241:831-8. doi:10.1148/radiol.2413051858
144. Griffith JF, Yeung DKW, Antonio GE, Lee FKH, Hong AWL, Wong SYS, et al. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology (2005) 236:945-51. doi:10.1148/ radiol.2363041425
145. Schwartz AV, Sigurdsson S, Hue TF, Lang TF, Harris TB, Rosen CJ, et al. Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. J Clin Endocrinol Metab (2013) 98:2294-300. doi:10.1210/jc.2012-3949
146. McGee-Lawrence ME, Carpio LR, Schulze RJ, Pierce JL, McNiven MA, Farr JN, et al. Hdac3 deficiency increases marrow adiposity and induces lipid storage and glucocorticoid metabolism in osteochondroprogenitor cells. J Bone Miner Res (2015) 31:116-28. doi:10.1002/jbmr.2602
147. Sinha P, Aarnisalo P, Chubb R, Ono N, Fulzele K, Selig M, et al. Loss of Gsa early in the osteoblast lineage favors adipogenic differentiation of mesenchymal progenitors and committed osteoblast precursors. J Bone Miner Res (2014) 29:2414-26. doi:10.1002/jbmr.2270
148. Urs S, Henderson T, Le P, Rosen CJ, Liaw L. Tissue-specific expression of Sprouty1 in mice protects against high-fat diet-induced fat accumulation, bone loss and metabolic dysfunction. Br J Nutr (2012) 108:1025-33. doi:10.1017/S0007114511006209
149. Motyl KJ, Raetz M, Tekalur SA, Schwartz RC, McCabe LR. CCAAT/ enhancer binding protein ß-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption. Am J Physiol Regul Integr Comp Physiol (2011) 300:R1250-60. doi:10.1152/ajpregu.007 64.2010
150. Colaianni G, Brunetti G, Faienza MF, Colucci S, Grano M. Osteoporosis and obesity: role of Wnt pathway in human and murine models. World J Orthop (2014) 5:242-6. doi:10.5312/wjo.v5.i3.242
151. de Paula FJA, de Araújo IM, Carvalho AL, Elias J, Salmon CEG, Nogueira-Barbosa MH. The relationship of fat distribution and insulin resistance with lumbar spine bone mass in women. PLoS One (2015) 10:e0129764. doi:10.1371/journal.pone.0129764
152. Templeton ZS, Lie W-R, Wang W, Rosenberg-Hasson Y, Alluri RV, Tamaresis JS, et al. Breast cancer cell colonization of the human bone marrow adipose tissue niche. Neoplasia (2015) 17:849-61. doi:10.1016/j. neo.2015.11.005
153. Takeshita S, Fumoto T, Naoe Y, Ikeda K. Age-related marrow adipogenesis is linked to increased expression of RANKL. J Biol Chem (2014) 289:16699-710. doi:10.1074/jbc.M114.547919
154. Wang D, Haile A, Jones LC. Dexamethasone-induced lipolysis increases the adverse effect of adipocytes on osteoblasts using cells derived from human mesenchymal stem cells. Bone (2013) 53:520-30. doi:10.1016/j. bone.2013.01.009
155. Kajimura D, Lee HW, Riley KJ, Arteaga-Solis E, Ferron M, Zhou B, et al. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through foxo1. Cell Metab (2013) 17:901-15. doi:10.1016/j. cmet.2013.04.009
156. Kennedy DE, Knight KL. Inhibition of B lymphopoiesis by adipocytes and IL-1-producing myeloid-derived suppressor cells. J Immunol (2015) 195:2666-74. doi:10.4049/jimmunol.1500957
157. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne M-N, Crinquette A, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia (2007) 21:158-63. doi:10.1038/sj.leu.2404466
158. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 17:1498-503. doi:10.1038/nm.2492
159. Gavin KM, Gutman JA, Kohrt WM, Wei Q, Shea KL, Miller HL, et al. De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue. FASEB J (2015) 30:1096-108. doi:10.1096/ fj.15-278994
160. Devlin MJ, Rosen CJ. The bone-fat interface: basic and clinical implications of marrow adiposity. Lancet Diabetes Endocrinol (2015) 3:141-7. doi:10.1016/ S2213-8587(14)70007-5
161. Ford NA, Devlin KL, Lashinger LM, Hursting SD. Deconvoluting the obesity and breast cancer link: secretome, soil and seed interactions. J Mammary Gland Biol Neoplasia (2013) 18:267-75. doi:10.1007/s10911-013-9301-9
162. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 117:3720-32. doi:10.1182/blood-2010-07-273417
163. Liou Y-H, Wang S-W, Chang C-L, Huang P-L, Hou M-S, Lai Y-G, et al. Adipocyte IL-15 regulates local and systemic NK cell development. J Immunol (2014) 193:1747-58. doi:10.4049/jimmunol.1400868
164. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother (2015) 38:24-36. doi:10.1097/CJI.0000000000000059
165. Rezzadeh KS, Hokugo A, Jewett A, Kozlowska A, Segovia LA, Zuk P, et al. Natural killer cells differentiate human adipose-derived stem cells and modulate their adipogenic potential. Plast Reconstr Surg (2015) 136:503-10. doi:10.1097/PRS.0000000000001536
166. Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I. Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev (2014) 33:527-43. doi:10.1007/s10555-013-9484-y
167. Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. Chem Rev (2011) 111:5944-72. doi:10.1021/cr200084z
168. Esterbauer H, Eckl P, Ortner A. Possible mutagens derived from lipids and lipid precursors. Mutat Res (1990) 238:223-33. doi:10.1016/0165-1110 (90)90014-3
169. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4:127-50. doi:10.1146/annurev.pathol.4.110807.092311
170. Martinez-Useros J, Garcia-Foncillas J. Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med (2016) 14:21. doi:10.1186/ s12967-016-0772-5
171. Eda H, Santo L, Wein MN, Hu DZ, Cirstea DD, Nemani N, et al. Regulation of sclerostin expression in multiple myeloma by Dkk-1; a potential therapeutic strategy for myeloma bone disease. J Bone Miner Res (2016) 31(6):1225-34. doi:10.1002/jbmr.2789
172. Brunetti G, Oranger A, Mori G, Specchia G, Rinaldi E, Curci P, et al. Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci (2011) 1237:19-23. doi:10.1111/j.1749-6632.2011.06196.x
173. Urs S, Venkatesh D, Tang Y, Henderson T, Yang X, Friesel RE, et al. Sprouty1 is a critical regulatory switch of mesenchymal stem cell lineage allocation. FASEB J (2010) 24:3264-73. doi:10.1096/fj.10-155127
174. Wei S, Zhang L, Zhou X, Du M, Jiang Z, Hausman GJ, et al. Emerging roles of zinc finger proteins in regulating adipogenesis. Cell Mol Life Sci (2013) 70:4569-84. doi:10.1007/s00018-013-1395-0
175. Shen W, Velasquez G, Chen J, Jin Y, Heymsfield SB, Gallagher D, et al. Comparison of the relationship between bone marrow adipose tissue and volumetric bone mineral density in children and adults. J Clin Densitom (2014) 17:163-9. doi:10.1016/j.jocd.2013.02.009
176. Martin RB, Zissimos SL. Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone (1991) 12:123-31. doi:10.1016/8756-3282(91)90011-7
177. Bonnet N, Somm E, Rosen CJ. Diet and gene interactions influence the skeletal response to polyunsaturated fatty acids. Bone (2014) 68:100-7. doi:10.1016/j.bone.2014.07.024
178. Styner M, Pagnotti GM, Galior K, Wu X, Thompson WR, Uzer G, et al. Exercise regulation of marrow fat in the setting of PPAR? agonist treatment in female C57BL/6 mice. Endocrinology (2015) 156:2753-61. doi:10.1210/ en.2015-1213
179. Meier C, Schwartz AV, Egger A, Lecka-Czernik B. Effects of diabetes drugs on the skeleton. Bone (2016) 82:93-100. doi:10.1016/j.bone.2015.04.026
180. Hanson DJ, Nakamura S, Amachi R, Hiasa M, Oda A, Tsuji D, et al. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation. Oncotarget (2015) 6:33568-86. doi:10.18632/ oncotarget.5598
181. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med (2014) 2:57. doi:10.3978/j.issn.2305-5839. 2014.06.01
182. Abdi J, Garssen J, Faber J, Redegeld FA. Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. J Nutr Biochem (2014) 25:1254-62. doi:10.1016/j.jnutbio.2014.06.013
183. Jia L, Liu F-T. Why bortezomib cannot go with "green"? Cancer Biol Med (2013) 10:206-13. doi:10.7497/j.issn.2095-3941.2013.04.004